FDA Orange Book · active-ingredient family
Mepivacaine hydrochloride
Mepivacaine hydrochloride is approved as 2 brand and 14 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:CARBOCAINE · NDA 012125
2
Brand (NDA)
14
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · injectable
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| CARBOCAINERLD | EASTMAN KODAK | NDA 012125 | — | Approved Prior to Jan 1, 1982 | |
| CARBOCAINERLD×3 | HOSPIRA | NDA 012250 | — | Approved Prior to Jan 1, 1982 |
Generic (ANDA) products (14)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| MEPIVACAINE HYDROCHLORIDE | HOSPIRA INC | ANDA 040806 | — | Apr 28, 2008 | |
| POLOCAINE | FRESENIUS KABI USA | ANDA 089407 | — | Dec 01, 1986 | |
| POLOCAINE | FRESENIUS KABI USA | ANDA 089410 | — | Dec 01, 1986 | |
| POLOCAINE-MPF | FRESENIUS KABI USA | ANDA 089406 | — | Dec 01, 1986 | |
| POLOCAINE-MPF | FRESENIUS KABI USA | ANDA 089408 | — | Dec 01, 1986 | |
| POLOCAINE-MPF | FRESENIUS KABI USA | ANDA 089409 | — | Dec 01, 1986 | |
| MEPIVACAINE HYDROCHLORIDE | WATSON LABS | ANDA 088769 | — | Nov 20, 1984 | |
| MEPIVACAINE HYDROCHLORIDE | WATSON LABS | ANDA 088770 | — | Nov 20, 1984 | |
| SCANDONEST PLAIN | DEPROCO | ANDA 088387 | — | Oct 10, 1984 | |
| POLOCAINE | DENTSPLY PHARM | ANDA 088653 | — | Aug 21, 1984 | |
| MEPIVACAINE HYDROCHLORIDE | INTL MEDICATION SYS | ANDA 087509 | — | Oct 05, 1982 | |
| ARESTOCAINE HYDROCHLORIDE | SOLVAY | ANDA 084777 | — | Apr 18, 1982 | |
| ISOCAINE HYDROCHLORIDE | SEPTODONT | ANDA 080925 | — | Approved Prior to Jan 1, 1982 | |
| MEPIVACAINE HYDROCHLORIDE | BELMORA LLC | ANDA 083559 | — | Approved Prior to Jan 1, 1982 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Mepivacaine hydrochloride — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

